Steven Penegar

4.4k total citations
20 papers, 552 citations indexed

About

Steven Penegar is a scholar working on Surgery, Pathology and Forensic Medicine and Molecular Biology. According to data from OpenAlex, Steven Penegar has authored 20 papers receiving a total of 552 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Pathology and Forensic Medicine and 7 papers in Molecular Biology. Recurrent topics in Steven Penegar's work include Genetic factors in colorectal cancer (8 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Urinary and Genital Oncology Studies (5 papers). Steven Penegar is often cited by papers focused on Genetic factors in colorectal cancer (8 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Urinary and Genital Oncology Studies (5 papers). Steven Penegar collaborates with scholars based in United Kingdom, United States and Canada. Steven Penegar's co-authors include Richard S. Houlston, Peter Broderick, Emily L. Webb, Steven Lubbe, Daniel Chubb, Sara E. Dobbins, Matthew Frampton, P. Yussanne, Amy L. Sherborne and Ben Kinnersley and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Steven Penegar

20 papers receiving 546 citations

Peers

Steven Penegar
Katie A. Ashton Australia
Chiara Brando Italy
Nicole Sebbagh France
Mutsuko Ohnishi United States
Jill N. Vilaythong United States
Yuko Suemoto United States
Yasuhiro Oshimo Japan
O. I. Olopade United States
Maria Olivia Biasi Italy
Li E. Wang United States
Katie A. Ashton Australia
Steven Penegar
Citations per year, relative to Steven Penegar Steven Penegar (= 1×) peers Katie A. Ashton

Countries citing papers authored by Steven Penegar

Since Specialization
Citations

This map shows the geographic impact of Steven Penegar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Penegar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Penegar more than expected).

Fields of papers citing papers by Steven Penegar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Penegar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Penegar. The network helps show where Steven Penegar may publish in the future.

Co-authorship network of co-authors of Steven Penegar

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Penegar. A scholar is included among the top collaborators of Steven Penegar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Penegar. Steven Penegar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Nicholson, Steve, Juanita Crook, Nick Watkin, et al.. (2025). Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT). International Journal of Radiation Oncology*Biology*Physics. 123(1). 171–182. 1 indexed citations
2.
Au, Lewis, Zayd Tippu, Husayn Ahmed Pallikonda, et al.. (2025). Vasculo-immune modulatory effects of anti-VEGF therapy in metastatic clear cell renal cell carcinoma: The A-PREDICT trial.. Journal of Clinical Oncology. 43(5_suppl). 572–572. 1 indexed citations
3.
4.
Pettaway, Curtis A., Steve Nicholson, Philippe E. Spiess, et al.. (2022). The international penile advanced cancer trial (InPACT): The first phase III trial for squamous carcinoma of the penis with regional lymph node metastases.. Journal of Clinical Oncology. 40(6_suppl). TPS7–TPS7. 11 indexed citations
5.
Mostafid, Hugh, Núria Porta, Joanne Cresswell, et al.. (2020). CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer. British Journal of Urology. 125(6). 817–826. 28 indexed citations
6.
Mostafid, Hugh, Núria Porta, Jo Cresswell, et al.. (2019). 12 month results of CALIBER: A phase II randomised feasibility trial of chemoablation with MMC versus surgical management in low risk (LR) non-muscle invasive bladder cancer (NMIBC). European Urology Supplements. 18(1). e762–e763. 1 indexed citations
7.
8.
Mostafid, Hugh, Jo Cresswell, T.R. Leyshon Griffiths, et al.. (2018). Results of CALIBER: A phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer. European Urology Supplements. 17(2). e1062–e1063. 1 indexed citations
9.
Mostafid, Hugh, Joanne Cresswell, T.R. Leyshon Griffiths, et al.. (2018). PD66-04 RESULTS OF CALIBER: A PHASE II RANDOMISED FEASIBILITY TRIAL OF CHEMOABLATION VERSUS SURGICAL MANAGEMENT IN LOW RISK NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC). The Journal of Urology. 199(4S). 1 indexed citations
10.
Chubb, Daniel, Peter Broderick, Sara E. Dobbins, et al.. (2016). Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nature Communications. 7(1). 11883–11883. 124 indexed citations
11.
Morris, Eva, Steven Penegar, Nicola Whiffin, et al.. (2015). A Retrospective Observational Study of the Relationship between Single Nucleotide Polymorphisms Associated with the Risk of Developing Colorectal Cancer and Survival. PLoS ONE. 10(2). e0117816–e0117816. 8 indexed citations
12.
Chubb, Daniel, Peter Broderick, Matthew Frampton, et al.. (2015). Genetic Diagnosis of High-Penetrance Susceptibility for Colorectal Cancer (CRC) Is Achievable for a High Proportion of Familial CRC by Exome Sequencing. Journal of Clinical Oncology. 33(5). 426–432. 72 indexed citations
13.
Morris, Eva, Steven Penegar, Philip Quirke, et al.. (2013). A retrospective observational study of the relationship between family history and survival from colorectal cancer. British Journal of Cancer. 108(7). 1502–1507. 26 indexed citations
14.
Whiffin, Nicola, Peter Broderick, Steven Lubbe, et al.. (2011). MLH1-93G > A is a risk factor for MSI colorectal cancer. Carcinogenesis. 32(8). 1157–1161. 34 indexed citations
15.
Pittman, Alan, Philip Twiss, Peter Broderick, et al.. (2009). The CDH1‐160C>A polymorphism is a risk factor for colorectal cancer. International Journal of Cancer. 125(7). 1622–1625. 18 indexed citations
16.
Pittman, Alan, Peter Broderick, Kathleen E. Sullivan, et al.. (2008). CASP8 variants D302H and −652 6N ins/del do not influence the risk of colorectal cancer in the United Kingdom population. British Journal of Cancer. 98(8). 1434–1436. 46 indexed citations
17.
Webb, Emily L., Peter Broderick, Isabelle Chandler, et al.. (2008). Comprehensive analysis of common mitochondrial DNA variants and colorectal cancer risk. British Journal of Cancer. 99(12). 2088–2093. 29 indexed citations
18.
Penegar, Steven, Wendy Wood, Steven Lubbe, et al.. (2007). National study of colorectal cancer genetics. British Journal of Cancer. 97(9). 1305–1309. 39 indexed citations
19.
Bethke, Lara, Emily L. Webb, Gabrielle S. Sellick, et al.. (2007). Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1and colorectal cancer risk. BMC Cancer. 7(1). 123–123. 53 indexed citations
20.
Webb, Emily L., Matthew Rudd, Gabrielle S. Sellick, et al.. (2006). Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synonymous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14 704 first-degree relatives. Human Molecular Genetics. 15(21). 3263–3271. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Katie A. Ashton Breakdown of academic impact, for papers by Chiara Brando Breakdown of academic impact, for papers by Nicole Sebbagh Breakdown of academic impact, for papers by Mutsuko Ohnishi Breakdown of academic impact, for papers by Jill N. Vilaythong Breakdown of academic impact, for papers by Yuko Suemoto Breakdown of academic impact, for papers by Yasuhiro Oshimo Breakdown of academic impact, for papers by O. I. Olopade Breakdown of academic impact, for papers by Maria Olivia Biasi Breakdown of academic impact, for papers by Li E. Wang
Rankless by CCL
2026